{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T05:33:51Z","timestamp":1738388031635,"version":"3.35.0"},"reference-count":34,"publisher":"Japanese Society of Internal Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,2,1]]},"DOI":"10.2169\/internalmedicine.4076-24","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T22:10:54Z","timestamp":1724796654000},"page":"449-454","source":"Crossref","is-referenced-by-count":0,"title":["T-cell Large Granular Lymphocytic Leukemia with a &lt;i&gt;STAT3&lt;\/i&gt; Mutation Successfully Treated with Cord Blood Transplantation"],"prefix":"10.2169","volume":"64","author":[{"given":"Yoshihiro","family":"Tokunaga","sequence":"first","affiliation":[{"name":"Third Department of Internal Medicine, Yamaguchi University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukinori","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Yamaguchi University Hospital, Japan"},{"name":"Division of Blood Transfusion, Yamaguchi University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taishi","family":"Ando","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Yamaguchi University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensaku","family":"Katsuki","sequence":"additional","affiliation":[{"name":"Division of Hematology and Diabetes, Nagato General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Sakai","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Yamaguchi University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Fujioka","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Yamaguchi University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Nono","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Yamaguchi University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shuto General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Yamaguchi University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Akiyama","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Yamaguchi University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiro","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Hematology and Clinical Oncology, Shinshu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Hematology and Clinical Oncology, Shinshu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiro","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Hematology and Clinical Oncology, Shinshu University School of Medicine, Japan"},{"name":"Department of Biomedical Laboratory Sciences, Shinshu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuharu","family":"Ohta","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Yamaguchi University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Yujiri","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Yamaguchi University Hospital, Japan"},{"name":"Department of Laboratory Science, Yamaguchi University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Oshimi K. Clinical features, pathogenesis, and treatment of large granular lymphocyte leukemias. Intern Med 56: 1759-1769, 2017.","DOI":"10.2169\/internalmedicine.56.8881"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Cheon H, Xing JC, Moosic KB, et al. Genomic landscape of TCR\u03b1\u03b2 and TCR\u03b3\u03b4 T-large granular lymphocyte leukemia. Blood 139: 3058-3072, 2022.","DOI":"10.1182\/blood.2021013164"},{"key":"3","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1182\/blood.V84.7.2164.2164","volume":"84","author":"TP Loughran","year":"1994","unstructured":"3. Loughran TP Jr, Kidd PG, Starkebaum G. Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate. Blood 84: 2164-2170, 1994.","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Osuji N, Matutes E, Tjonnfjord G, et al. T-cell large granular lymphocyte leukemia: a report on the treatment of 29 patients and a review of the literature. Cancer 107: 570-578, 2006.","DOI":"10.1002\/cncr.22032"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Bareau B, Rey J, Hamidou M, et al. Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica 95: 1534-1541, 2010.","DOI":"10.3324\/haematol.2009.018481"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Moignet A, Hasanali Z, Zambello R, et al. Cyclophosphamide as a first-line therapy in LGL leukemia. Leukemia 28: 1134-1136, 2014.","DOI":"10.1038\/leu.2013.359"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Loughran TP Jr, Zickl L, Olson TL, et al. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia 29: 886-894, 2015.","DOI":"10.1038\/leu.2014.298"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Munir T, Bishton MJ, Carter I, et al. Single-center series of bone marrow biopsy-defined large granular lymphocyte leukemia: high rates of sustained response to oral methotrexate. Clin Lymph Myeloma Leuk 16: 705-712, 2016.","DOI":"10.1016\/j.clml.2016.08.014"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sanikommu SR, Clemente MJ, Chomczynski P, et al. Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL). Leuk Lymphoma 59: 416-422, 2018.","DOI":"10.1080\/10428194.2017.1339880"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Zhu Y, Gao Q, Hu J, Liu X, Guan D, Zhang F. Clinical features and treatment outcomes in patients with T-cell large granular lymphocytic leukemia: a single-institution experience. Leuk Res 90: 106299, 2020.","DOI":"10.1016\/j.leukres.2020.106299"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Braunstein Z, Mishra A, Staub A, Freud AG, Porcu P, Brammer JE. Clinical outcomes in T-cell large granular lymphocytic leukaemia: prognostic factors and treatment response. Br J Haematol 192: 484-493, 2021.","DOI":"10.1111\/bjh.16808"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Dong N, Tokumori FC, Isenalumhe L, et al. Large granular lymphocytic leukemia - a retrospective study of 319 cases. Am J Hematol 96: 772-780, 2021.","DOI":"10.1002\/ajh.26183"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Seebach J, Speich R, Gm\u00fcr J. Allogeneic bone marrow transplantation for CD3+\/TCR gamma delta+ large granular lymphocyte proliferation. Blood 85: 853, 1995.","DOI":"10.1182\/blood.V85.3.853.bloodjournal853853"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. La Nasa G, Littera R, Cocco E, Battistini L, Marrosu MG, Contu L. Allogeneic hematopoietic stem cell transplantation in a patient affected by large granular lymphocyte leukemia and multiple sclerosis. Ann Hematol 83: 403-405, 2004.","DOI":"10.1007\/s00277-003-0801-3"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Donato ML, Goldberg SL, Pecora AL, Rowley SD. Treatment of T cell large granular lymphocyte leukemia with reduced-intensity allogeneic stem cell transplantation. Blood 110: 4931, 2007.","DOI":"10.1182\/blood.V110.11.4931.4931"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Marchand T, Lamy T, Finel H, et al. Hematopoietic stem cell transplantation for T-cell large granular lymphocyte leukemia: a retrospective study of the European Society for Blood and Marrow Transplantation. Leukemia 30: 1201-1204, 2016.","DOI":"10.1038\/leu.2015.256"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Carey E, Ward N, Abdul-Hay M. Large granular lymphocytic leukemia cured by allogeneic stem cell transplant: a case report. J Med Case Rep 16: 227, 2022.","DOI":"10.1186\/s13256-022-03447-y"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Fries C, Evans AG, Cheon H, Korones DN, Loughran TP Jr, Andolina JR. Allogeneic bone marrow transplant as a cure for refractory T-cell large granular lymphocytic leukemia in an adolescent. J Pediatr Hematol Oncol 44: e960-e963, 2022.","DOI":"10.1097\/MPH.0000000000002390"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ishida F, Matsuda K, Sekiguchi N, et al. <i>STAT3<\/i> gene mutations and their association with pure red cell aplasia in large granular lymphocyte leukemia. Cancer Sci 105: 342-346, 2014.","DOI":"10.1111\/cas.12341"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kawakami T, Sekiguchi N, Kobayashi J, et al. <i>STAT3<\/i> mutations in natural killer cells are associated with cytopenia in patients with chronic lymphoproliferative disorder of natural killer cells. Int J Hematol 109: 563-571, 2019.","DOI":"10.1007\/s12185-019-02625-x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kawakami T, Sekiguchi N, Kobayashi J, et al. Frequent <i>STAT3<\/i> mutations in CD8<sup>+<\/sup> T cells from patients with pure red cell aplasia. Blood Adv 2: 2704-2712, 2018.","DOI":"10.1182\/bloodadvances.2018022723"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kawakami F, Kawakami T, Yamane T, et al. T cell clonal expansion and <i>STAT3<\/i> mutations: a characteristic feature of acquired chronic T cell-mediated pure red cell aplasia. Int J Hematol 115: 816-825, 2022.","DOI":"10.1007\/s12185-022-03310-2"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Qiu ZY, Fan L, Wang L, et al. STAT3 mutations are frequent in T-cell large granular lymphocytic leukemia with pure red cell aplasia. J Hematol Oncol 6: 82, 2013.","DOI":"10.1186\/1756-8722-6-82"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Taira C, Matsuda K, Kamijyo Y, et al. Quantitative monitoring of single nucleotide mutations by allele-specific quantitative PCR can be used for the assessment of minimal residual disease in patients with hematological malignancies throughout their clinical course. Clin Chim Acta 412: 53-58, 2011.","DOI":"10.1016\/j.cca.2010.09.011"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Braunstein Z, McLaughlin E, Mishra A, Brammer JE. Cyclophosphamide induces durable molecular and clinical responses in patients with relapsed T-LGL leukemia. Blood Adv 6: 2685-2687, 2022.","DOI":"10.1182\/bloodadvances.2021006263"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Imahashi N, Terakura S, Kondo E, et al. Impact of donor types on reduced-intensity conditioning allogeneic stem cell transplant for mature lymphoid malignancies. Bone Marrow Transplant 57: 243-251, 2022.","DOI":"10.1038\/s41409-021-01525-1"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Imahashi N, Terakura S, Kondo E, et al. Comparison of reduced-intensity\/toxicity conditioning regimens for umbilical cord blood transplantation for lymphoid malignancies. Bone Marrow Transplant 55: 2098-2108, 2020.","DOI":"10.1038\/s41409-020-0905-6"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. Shimoni A, Hardan I, Shem-Tov N, et al. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine\/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine\/busulfan. Leukemia 21: 2109-2116, 2007.","DOI":"10.1038\/sj.leu.2404886"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Pi\u00f1ana JL, Valc\u00e1rcel D, Fern\u00e1ndez-Avil\u00e9s F, et al. MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings. Bone Marrow Transplant 45: 1449-1456, 2010.","DOI":"10.1038\/bmt.2009.362"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30. Ciurea SO, Zhang MJ, Bacigalupo AA, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood 126: 1033-1040, 2015.","DOI":"10.1182\/blood-2015-04-639831"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Kanate AS, Mussetti A, Kharfan-Dabaja MA, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood 127: 938-947, 2016.","DOI":"10.1182\/blood-2015-09-671834"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Gu Z, Wang L, Yuan L, et al. Similar outcomes after haploidentical transplantation with post-transplant cyclophosphamide versus HLA-matched transplantation: a meta-analysis of case-control studies. Oncotarget 8: 63574-63586, 2017.","DOI":"10.18632\/oncotarget.18862"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Gagelmann N, Bacigalupo A, Rambaldi A, et al. Haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy vs other donor transplantations in adults with hematologic cancers: a systematic review and meta-analysis. JAMA Oncol 5: 1739-1748, 2019.","DOI":"10.1001\/jamaoncol.2019.3541"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Atsuta Y, Sugita J, Nakamae H, et al. Comparable survival outcomes with haploidentical stem cell transplantation and unrelated bone marrow transplantation. Bone Marrow Transplant 57: 1781-1787, 2022.","DOI":"10.1038\/s41409-022-01822-3"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/3\/64_4076-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T03:37:05Z","timestamp":1738381025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/3\/64_4076-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4076-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2025,2,1]]},"article-number":"4076-24"}}